Scrip Asks... What Does 2026 Hold For Biopharma? Part 2: Competitive Dynamics

Regulatory divergence across major markets is creating strategic complexity that compounds geographic competitive pressures.

Read the full article featuring Allison Cuff Shimooka from Citeline here.

Previous Blog Post

Next Blog Post

Jan 16

TransCelerate CEO Janice Chang wants trials to become part of routine care

Jan 23

Digital Protocols Are At An Inflection Point: A Conversation With Novartis And TransCelerate Leaders

Related Blog Posts

Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation

Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological advances to enable breakthroughs in processes as well as pipelines. Read the full article featuring Rob DiCicco from Citeline here.

Trendspotting: Embracing AI, DEI Changes, Restrategizing Research Sites

To kick off 2026, we spoke with industry experts and leaders in the Clinical Research News community about what they expect and look forward to in the new year. More than ever before, artificial intelligence took center stage. Read the full article featuring Allison Cuff Shimooka from Clinical Research News here.

Trendspotting: Artificial Intelligence, Impact of Global Policies, Data Harmonization

To kick off 2026, we spoke with industry experts and leaders in the Bio-IT World community about what they expect and look forward to in the new year. Read the full article featuring Allison Cuff Shimooka from Bio-It World here.